Novartis reports positive interim results for Fabhalta
In the analysis, patients treated with Fabhalta achieved a clinically and statistically significant 38.3% reduction in proteinuria at nine months, compared with placebo plus supportive care.
The primary endpoint, assessing Fabhalta's ability to slow IgAN progression by measuring the annualized slope of total glomerular filtration rate (eGFR) over 24 months, is expected at the end of the study in 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction